

Special Issue

Antibody Therapeutics against Infectious Disease

Message from the Guest Editors

Bioengineering is currently soliciting manuscripts for a special issue focusing on novel antibody therapeutics used to treat infectious disease. Manuscripts can include literature reviews as well as primary research papers. Topics of particular interest include platforms for rapid discovery of antibodies, bispecific antibodies, strategies for rapid manufacturing to respond to emerging diseases, and repurposing of existing antibody therapeutics for novel indications in infectious disease. Submissions related to treatment of SARS-CoV2/COVID19 are particularly encouraged, but papers addressing other infectious diseases such as respiratory syncytial virus (RSV), Zika and Ebola viruses are also welcome. Submissions are requested by May 2021 and will be peer-reviewed and published once submitted, possible publication date September 2021. Bioengineering (ISSN 2306-5354; CODEN: BIOENG) is an international scientific peer-reviewed, open access journal on the science and technology of bioengineering, published monthly online by MDPI.

Guest Editors

Prof. Dr. Susan Sharfstein

College of Nanoscale Science and Engineering, The State University of New York Polytechnic Institute, Albany, NY 12203, USA

Dr. Hanieh Khalili

School of biomedical science, University of West London, London W5 5RF, UK

Deadline for manuscript submissions

closed (31 May 2021)



Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 4.0
Indexed in PubMed



mdpi.com/si/70188

Bioengineering

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
bioengineering@mdpi.com

[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)





Bioengineering

an Open Access Journal
by MDPI

Impact Factor 3.8
CiteScore 4.0
Indexed in PubMed



[mdpi.com/journal/
bioengineering](https://mdpi.com/journal/bioengineering)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical Engineering, Texas A&M University, College Station, TX 77843, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPIus / SciFinder, Inspec, and other databases.

Journal Rank:

JCR - Q2 (Engineering, Biomedical) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.